MedTrace Logo

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

NCT01557127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 205

Last updated 2017-03-28

No results posted yet for this study

Summary

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-01
Primary Completion
2014-05-16
Completion
2016-03-31

Countries

  • Poland

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01557127 on ClinicalTrials.gov